[Pharmacokinetic and clinical studies with @entity2892 / @entity9234 in the pediatric field. Pediatric Study Group for XXXX / @entity9234 ].

@entity1 @entity1997 @entity2892 @entity295 @entity796 @entity55 @entity9234 @entity794 @entity693 @entity2893 @entity1729 @entity293 @entity15644
Pharmacokinetic and clinical studies of @entity2892 / @entity9234 ( @entity2892 / @entity9234 ), a new @entity2893 antibiotic and a @entity15644 inhibitor, respectively, were carried out in a joint study in the pediatric field by a study group consisting of investigators at 16 institutions. The results were summarized below. Pharmacokinetic studies Peak plasma concentrations of @entity2892 / @entity9234 were 27.7-190.0/28.3-216.4 micrograms/ml at doses of 10/10-50/50 mg/kg administered by a 30 or 60-minute drip infusion. The above findings proved that dose response was clearly observed. Over a period of 6 or 7 hours, the urinary excretion of @entity2892 and @entity9234 totaled 54.2-88.0% and 53.6-89.0% of the dose administered, respectively. Plasma half-lives of @entity2892 and @entity9234 in the beta-phase were 0.87-1.05 hours and 0.59-0.95 hour, respectively. The cerebrospinal fluid (CSF) levels of @entity2892 in @entity1 with @entity693 were 2.0-14.4 micrograms/ml; however, the penetration rate of the drug into the CSF was relatively poor in @entity1 with normal meninges. Clinical study Clinical efficacy was evaluated in 283 @entity1 . In 112 @entity1 the daily dosage ranged from 30/30 mg/kg to 59/59 mg/kg, and in 138 @entity1 it ranged from 60/60 mg/kg to 99/99 mg/kg. The maximum dose administered was 222/222 mg/kg. The drug was administered either 3 or 4 times per day. The clinical efficacy rate was 92.5% among 187 @entity1 with identified etiologic pathogens. The drug was effective in 3 out of 4 @entity1 with @entity693 and in 7 out of 10 @entity1 with @entity295 . The clinical efficacy rate was 96.7% in 90 @entity1 with @entity1729 ( @entity55 , @entity1997 , etc.), 96.5% in 57 @entity1 with @entity293 , 90.9% in 11 @entity1 with SSTI. The clinical efficacy rate in those with no identified etiologic pathogen was 97.0% among 101 @entity1 . Bacteriologically, the eradication rate for @entity794 was 87.9% of 33 isolates. Comprehensively, the eradication rate for Gram-positive bacteria was 94.7% of 75 isolates. The eradication rate for @entity796 was 87.5% of 8 isolates. Including these strains, the eradication rate for Gram-negative bacteria was 90.3% of 134 isolates. The @entity2892 / @entity9234 exhibited an eradication rate of 91.9% among a total of 211 Gram-positive and Gram-negative bacteria including anaerobes.(ABSTRACT TRUNCATED AT 400 WORDS)
